tiprankstipranks
Laboratorios Farmaceuticos Rovi, SA (GB:0ILL)
LSE:0ILL
Holding GB:0ILL?
Track your performance easily

Laboratorios Farmaceuticos Rovi (0ILL) Financial Statements

0 Followers

Laboratorios Farmaceuticos Rovi Financial Overview

Laboratorios Farmaceuticos Rovi's market cap is currently ―. The company's EPS TTM is €3.22; its P/E ratio is 19.18; and it has a dividend yield of 1.42%. Laboratorios Farmaceuticos Rovi is scheduled to report earnings on March 4, 2025, and the estimated EPS forecast is €―. See an overview of income statement, balance sheet, and cash flow financials.
Dec 22Sep 22Jun 22Mar 22Dec 21
Income Statement-
Total Revenue€ 242.20M€ 195.10M€ 174.82M€ 205.58M€ 185.18M
Gross Profit€ 176.51M€ 116.79M€ 101.63M€ 124.69M€ 119.05M
EBIT€ 99.97M€ 52.85M€ 36.63M€ 69.13M€ 58.28M
EBITDA€ 105.80M€ 58.58M€ 42.38M€ 74.69M€ 63.39M
Net Income Common Stockholders€ 78.17M€ 40.88M€ 27.57M€ 53.05M€ 54.14M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments€ 124.94M€ 97.64M€ 158.85M€ 101.74M€ 99.03M
Total Assets€ 878.70M€ 772.47M€ 791.57M€ 744.86M€ 732.68M
Total Debt€ 72.14M€ 73.62M€ 73.13M€ 0.00€ 73.14M
Net Debt€ -52.81M€ -24.02M€ -85.72M€ -101.74M€ -25.89M
Total Liabilities€ 357.32M€ 329.18M€ 391.21M€ 319.16M€ 261.70M
Stockholders Equity€ 520.01M€ 441.92M€ 399.02M€ 425.55M€ 470.98M
Cash Flow-
Free Cash Flow€ 34.64M€ -7.96M€ 57.54M€ 102.00M€ -7.47M
Operating Cash Flow€ 67.57M€ 593.00K€ 65.33M€ 104.11M€ 11.49M
Investing Cash Flow€ -38.80M€ -8.48M€ -7.77M€ -2.11M€ -18.96M
Financing Cash Flow€ -1.46M€ -52.10M€ -1.68M€ -99.30M€ -37.46M
Currency in EUR

Laboratorios Farmaceuticos Rovi Earnings and Revenue History

Laboratorios Farmaceuticos Rovi Debt to Assets

Laboratorios Farmaceuticos Rovi Cash Flow

Laboratorios Farmaceuticos Rovi Forecast EPS vs Actual EPS

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis